Skip to content

库拉肿瘤

US · KURA #3283 按市值排名 上市于 2015
9.08 -0.62 -6.39%
实时 - 追踪5344个代码 - 心跳于389秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

增持
  • 机构持股总比例上升了0.1个百分点。

机构持股

机构持股比例
99.52% +0.13pp
机构数量
271
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund53.11%
Hedge Fund35.53%
Public Company4.89%
VC/PE Fund4.10%
Individual/Insider1.59%
Private Company1.24%
Government Pension Fund0.40%
Insurance Company0.18%

主要股东 截至 2026-06-30

BlackRock 11.81% · 10.51M 股
Montanova Capital, LLC 9.64% · 8.58M 股
BVF Partners L.P. 9.49% · 8.45M 股
State Street Global Advisors 5.99% · 5.33M 股
Vanguard Capital Management, LLC 5.11% · 4.55M 股
Armistice Capital LLC 4.13% · 3.68M 股
AQR Capital Management 3.46% · 3.08M 股
Geode Capital Management, LLC 2.51% · 2.23M 股
Alethea Capital Management, LLC 2.44% · 2.17M 股
Prosight Management, LP 2.27% · 2.02M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 26次买入 · 24次卖出

姓名职务持股比例
Troy Wilson Chairperson & CEO 1.16%
Kathleen Ford Chief Operating Officer 0.10%
Teresa Bair Chief Legal Officer 0.08%
Thomas Doyle Senior VP of Finance & Accounting 0.08%
Francis Burrows Senior Vice President of Translational Research 0.05%
Mollie Leoni Executive Vice President of Clinical Development 0.05%
Faheem Hasnain Lead Independent Director 0.03%
Brian Powl Chief Commercial Officer 0.02%
Thomas Malley Independent Director 0.01%
Stephen Dale Chief Medical Officer 0.00%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-28 Kathleen Ford Chief Operating Officer Automatic Disposition -3,668 $10.75
2026-09-28 Brian Powl Chief Commercial Officer Automatic Disposition -23,430 $10.56–10.75
2026-09-28 Brian Powl Chief Commercial Officer Intent to Sell (Form 144) -15,430 $10.61
2026-09-28 Mollie Leoni Executive Vice President of Clinical Development Automatic Disposition -28,802 $10.75
2026-09-27 Teresa Bair Chief Legal Officer Open Market Disposition -8,442 $10.50
2026-09-27 Kathleen Ford Chief Operating Officer Open Market Disposition -6,906 $10.50
2026-09-27 Brian Powl Chief Commercial Officer Open Market Disposition -9,020 $10.50
2026-09-27 Mollie Leoni Executive Vice President of Clinical Development Open Market Disposition -12,448 $10.50
2026-09-27 Thomas Doyle Senior VP of Finance & Accounting Open Market Disposition -4,607 $10.50
2026-09-23 Francis Burrows Senior Vice President of Translational Research Derivative Exercise and Sale -20,726 $6.15–10.83
2026-09-23 Francis Burrows Senior Vice President of Translational Research Derivative Exercise and Retained +9,274 $6.15
2026-09-07 Jennifer Fulk Chief Financial Officer Other Derivative Acquisition +450,000 $12.52
2026-08-23 Troy Wilson Chairperson & CEO Open Market Acquisition +100,000 $12.39
2026-08-20 Brian Powl Chief Commercial Officer Open Market Disposition -4,345 $11.89
2026-08-18 Teresa Bair Chief Legal Officer Automatic Disposition -31,487 $12.63
2026-08-16 Troy Wilson Chairperson & CEO Open Market Acquisition +100,000 $11.12
2026-06-17 Mollie Leoni Executive Vice President of Clinical Development Automatic Disposition -84,929 $9.82
2026-06-03 Diane Parks Independent Director Other Derivative Acquisition +35,000 $8.77
2026-06-03 Thomas Malley Independent Director Other Derivative Acquisition +35,000 $8.77
2026-06-03 Mary Szela Independent Director Other Derivative Acquisition +35,000 $8.77

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:33 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

库拉肿瘤 讨论区 0 条评论

发表评论